| Trial ID: | L4573 |
| Source ID: | NCT00120536
|
| Associated Drug: |
Vildagliptin
|
| Title: |
Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: vildagliptin
|
| Outcome Measures: |
Primary: Change from baseline in HbA1c at 24 weeks | Secondary: Adverse event profile after 24 weeks of treatment|Change from baseline in fasting plasma glucose at 24 weeks|Patients with endpoint HbA1c < 7% after 24 weeks|Patients with reduction in HbA1c >/= 0.7% after 24 weeks|Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c
|
| Sponsor/Collaborators: |
Sponsor: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
288
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-06
|
| Completion Date: |
2006-07
|
| Results First Posted: |
|
| Last Update Posted: |
2017-05-18
|
| Locations: |
Novartis Pharmaceuticals, East Hanover, New Jersey, 07936, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00120536
|
